8.00
8.00 (0%)
As of Sep 12, 2023
First Light Acquisition Group, Inc. [FLAG]
Source:
Company Overview
Calidi Biotherapeutics, Inc. is a clinical stage immuno-oncology company that is developing proprietary allogeneic stem cell-based and enveloped virus platformsto potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | (858) 794-9600 |
| Industry | manufacturing |
| CEO | Allan J. Camaisa |
| Website | www.calidibio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-21.8 |
| Net Income | $-22.2 |
| Net Cash | $7.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -183.5% |
| Profit as % of Stockholder Equity | -1,128.5% |
Management Effectiveness
| Return on Equity | -1,128.5% |
| Return on Assets | -156.6% |
| Turnover Ratio | |
| EBITA | $-21.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $14.2 |
| Total Liabilities | $12.2 |
| Operating Cash Flow | $-19.7 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $27.4 |
